Abbott Laboratories vs. Protagonist Therapeutics, Inc
Abbott Laboratories (ABT) comes out ahead, leading on 8 of 9 compared factors.
Size & Scale
| ABT | PTGX | |
|---|---|---|
| Market Cap | $175.27 billion | $9.18 billion |
| Revenue (TTM) | $46.59 billion | $281.99 million |
| Net Income (TTM) | $5.42 billion | $82.91 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | PTGX | |
|---|---|---|
| P/E Ratio | 32.78 | 138.14 |
| Price / Book | 3.39 | 10.91 |
| Price / Sales | 3.76 | 32.55 |
ABT leads on 3 of 3 valuation factors.
Profitability
| ABT | PTGX | |
|---|---|---|
| Net Margin | 11.65% | 29.40% |
| Return on Equity | 10.48% | 9.85% |
ABT and PTGX split the profitability factors evenly.
Dividend
| ABT | PTGX | |
|---|---|---|
| Dividend Yield | 2.49% | — |
| Payout Ratio | 81.55 | — |
ABT and PTGX split the dividend factors evenly.
Risk & Sentiment
| ABT | PTGX | |
|---|---|---|
| Short Interest | 0.57% | 0.62% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, PTGX overview, PTGX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.